Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

The Most Effective Therapeutic Regimen for Patients with Severe Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection

Tawalah HA1, Al-Qabandi S1, Sadiq M1, Chehadeh C2, Al-Hujailan G3 and Al-Qaseer M1*
1Clinical Virology Unit, Mubarak Al Kabeer Hospital/Health Science Centre, Kuwait
2Department of Microbiology, Health Science Centre, University of Kuwait, Kuwait
3Infectious Diseases Unit, AlAddan Hospital, Kuwait
Corresponding Author : Mamoun Al-Qaseer
Faculty of Clinical Virology
Kuwait Institute for Medical Specialization
P.O. Box 1793, Safat, 13018, Kuwait
Tel: +96524636529
E-mail: dr.almamoun@gmail.com
Received: March 23, 2015 Accepted: July 06, 2015 Published: July 13, 2015
Citation: Tawalah HA, Al-Qabandi S, Sadiq M, Chehadeh C, Al-Hujailan G et al. (2015) The Most Effective Therapeutic Regimen for Patients with Severe Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection. J Infect Dis Ther 3:223. doi:10.4172/2332-0877.1000223
Copyright: © 2015 Tawalah AH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google

Abstract

Background: More than two years after its discovery, the Middle East respiratory syndrome coronavirus (MERSCoV) continues to have a high case-fatality rate. A specific therapy with proven effectiveness for MERS-CoV infections still does not exist.

Method: MERSCoV-positive patients were treated with different suggested treatment options. The virological and clinical progress of these patients in response to the treatment was evaluated.

Results: Both patients had co-morbidities and were critically ill with acute respiratory distress syndrome on mechanical ventilation at the time of diagnosis. Even though low dose ribavirin/ pegylated interferon α combination was started early for the first patient, it was provided late for the second patient. Both patients recovered from their infection.

Conclusion: By evaluating the clinical and virological response of the patients to the different treatment options implicated, it seems that currently the most effective therapy against severe MERS-CoV infection is the low dose ribavirin/ pegylated interferon α combination.

Keywords

Top